Terazosin

WikiDoc Resources for Terazosin
Articles
Most recent articles on Terazosin Most cited articles on Terazosin Review articles on Terazosin Articles on Terazosin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Terazosin Images of Terazosin Photos of Terazosin Podcasts & MP3s on Terazosin Videos on Terazosin
Evidence Based Medicine
Cochrane Collaboration on Terazosin Bandolier on Terazosin TRIP on Terazosin
Clinical Trials
Ongoing Trials on Terazosin at Clinical Trials.gov Trial results on Terazosin Clinical Trials on Terazosin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Terazosin NICE Guidance on Terazosin NHS PRODIGY Guidance FDA on Terazosin CDC on Terazosin
Books
Books on Terazosin
News
Terazosin in the news Be alerted to news on Terazosin News trends on Terazosin
Commentary
Blogs on Terazosin
Definitions
Definitions of Terazosin
Patient Resources / Community
Patient resources on Terazosin Discussion groups on Terazosin Patient Handouts on Terazosin Directions to Hospitals Treating Terazosin Risk calculators and risk factors for Terazosin
Healthcare Provider Resources
Symptoms of Terazosin Causes & Risk Factors for Terazosin Diagnostic studies for Terazosin Treatment of Terazosin
Continuing Medical Education (CME)
CME Programs on Terazosin
International
Terazosin en Espanol Terazosin en Francais
Business
Terazosin in the Marketplace Patents on Terazosin
Experimental / Informatics
List of terms related to Terazosin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Synonyms / Brand Names: Terazosin HCl, Terazosin hydrochloride, Terazosina, Terazosine, Terazosinum, Trazosin HCl, Abbott 45975, Blavin, Flumarc, Fosfomic, Heitrin, Hytracin, Hytrin, Hytrinex, Itrin, Urodie, Vasocard, Vasomet, Vicard

Dosing and Administration

Benign prostatic hyperplasia

• Initial dose: 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded as an initial dose. Patients should be closely followed during initial administration in order to minimize the risk of severe hypotensive response.

Hypertension

• Initial dose: 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. This initial dosing regimen should be strictly observed to minimize the potential for severe hypotensive effects.

Adapted from the FDA Package Insert. Template:SIB Template:WH Template:WS